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Abstract
Osteonecrosis as term represents the death of bone tissue in the body and causes 
of necrosis can be different. Medication-related osteonecrosis of the jaws (MRONJ) 
is nowadays known as an inability of the alveolar bone to respond to a local trauma 
and it can result in severe local and systemic complications. In the etiology of 
medication-related osteonecrosis there are antiangiogenic and antiresorptive agents 
which have great effect on alveolar bone, producing an imbalance between resorp-
tion (osteoclastic activity) and deposition (osteoblastic activity). The exact mecha-
nisms of development are not todays completely resolved. It is thought that it is a 
result from combination of medication interactions, microbiological contamination 
of the area and local tissue trauma. Typical signs and symptoms are painful mucosal 
lesions, swelling, exposed necrotic bone in the jaws, discomfort and dysesthesias. 
There is currently no gold standard or clearly defined treatment protocol for the 
disease itself. Process of treatment is demanding and main goal is to eliminate pain, 
control infection of soft and hard tissue and minimize progression of osteonecrosis. 
Besides the conventional surgical treatment, photodynamic therapy can be a viable 
supportive tool of initial and advanced stages of osteonecrosis and may contribute 
to improvements of patient′s quality of life.
Keywords: osteonecrosis, osteoclasts, bone, surgical procedure, photodynamic 
therapy
1. Introduction
Osteonecrosis as term represents the death of bone tissue in the body and causes 
of necrosis can be different. If it is associated with a reduced or complete absence 
of blood supply, this process is called avascular necrosis of the bone and is most 
commonly associated in the literature with the femur bone [1].
Radiotherapy (radiation) can also adversely affect bone tissue due to compro-
mised angiogenesis resulting in avascular necrosis with hypoxic, hypocellular, 
and hypovascular lesions, termed osteoradionecrosis [1]. In 2003, when 36 cancer 
patients receiving treatment with pamidronate or zoledronate developed a painful 
bone exposure of the mandible, of the maxilla or both, which was unresponsive to 
medical and surgical treatment, a new type of osteonecrosis of the jawbone  
associated with bisphosphonate was called osteonecrosis of the jaw (BRONJ) [2].  
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Over time, precisely in 2010, new drugs have been identified, such as denosumab 
for causing osteonecrosis, that do not belong to the group of bisphosphonates so 
the name has changed to medication-related osteonecrosis of the jaw (MRONJ) [3]. 
MRONJ is an uncommon condition that can occur after exposure to medication to 
prevent bone complications, such as bisphosphonates or denosumab or other agents 
as angiogenesis inhibitors [4]. In most cases it manifests as exposed bone in the 
maxillofacial region, although non-exposed MRONJ has also been recognized [5–8].
The purpose of this chapter was to describe medication-related osteonecrosis of 
the jaw, the theory of its development, clinical picture, classification, epidemiology 
and modalities of treatment, including biostimulative and antimicrobial photody-
namic therapy, of medication-related osteonecrosis of the jaw.
2. The process of bone remodeling
Bone remodeling is a physiological process that lasts lifetime and is character-
ized by the interaction of bone-forming cells - osteoblasts and bone-resorbing 
cells - osteoclasts. The remodeling process begins with the activation of osteoclasts 
(multinuclear cells of the monocyte–macrophage system) which are located on the 
bone surface and with the formation of acidic medium, they dissolve mineralized 
bone with the breakdown of proteins of the remaining bone matrix. This resorption 
process takes between two and four weeks. After the resorption process, osteoblasts 
replace osteoclasts (cells of mesenchymal origin) which synthesize osteoid and 
organic matrix over a period of two to four months, as a prerequisite for bone min-
eralization or calcium hydroxyapatite mineral investment [2]. Finally, when osteo-
blasts are implanted in the bone matrix, they become osteocytes [3]. The presence 
of osteocytes is extremely important for bone vitality because they can recognize 
and respond to a variety of mechanical stimuli by regulating the differentiation of 
osteoblasts and osteoclasts. The remodeling process is regulated by various mecha-
nisms, of which the most important is the RANK/RANKL/Osteoprotergin system. 
Osteoblasts secrete osteoprotergin, which prevents osteoclast differentiation from 
precursor cells and thus inhibits resorption. On the other hand, RANKL (Receptor 
Activator of NF-kb Ligand) along with M-CSF (Macrophage Colony-Stimulating 
Factor) stimulates osteoclast differentiation and maturation from precursor cells 
[4]. If this physiological process is disturbed, and this is especially important with 
increased expression of RANKL, resorption occurs. RANKL is produced by osteo-
blasts and activated T lymphocytes.
During remodeling and healing of bone fractures, osteoblasts activate various 
bone morphogenetic proteins that stimulate the production of VEGF (Vascular 
Endothelial Growth Factor) factor, which is necessary for the formation of new 
blood vessels, or angiogenesis [5].
The process of physiological remodeling can be disrupted in a variety of diseases 
and conditions associated with hyperactivated osteoclasts that have a high potential 
for bone destruction, which can result in hypercalcemia, decreased bone density, 
and consequent spontaneous fractures. The most common metabolic disease of the 
skeletal system is osteoporosis which is characterized by osteoclast hyperactivity 
with loss of bone quality. Malignant diseases of the breast, prostate, lungs, kidneys 
and thyroid often metastasize to bone. Complications of bone metastases include 
bone pain, fractures, hypercalcemia, and cachexia. Once formed in the bones, 
malignant cells stimulate bone resorption where various growth factors, released 
during bone destruction from the bone matrix, serve them for further growth and 
proliferation. In addition to growth factors, VEGF factor is also important for later 
tumor growth. Multiple myeloma, a malignant hematological disease, which is 
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manifested by the presence of lytic lesions in the bone, has a similar mechanism 
of bone destruction. In the treatment of these diseases, antiresorptive drugs that 
directly or indirectly inhibit osteoclasts and antiangiogenic drugs that inhibit VEGF 
are used.
3. Medications-related osteonecrosis of the jaw (MRONJ)
There are two groups of drugs that may cause medication-related osteonecrosis 
of the jaw. The first group includes antiresorptive drugs, specifically bisphospho-
nates and denosumabs, and the second group consists of antiangiogenic drugs that 
include bevacizumab (Avastin) which is humanized monoclonal antibody and also 
sunitinib (Sutent) which acts as a thyroxine kinase inhibitor [9–13].
3.1 Antiresorptive drugs
The first type of drugs is antiresorptive drugs, which include bisphosphonates 
and denosumabs. They have a similar mechanism of action and a similar potency of 
causing osteonecrosis.
3.1.1 Bisphosphonates
Bisphosphonates are medications that act as analogs of pyrophosphate, which is 
a natural inhibitor of bone metabolism. The mechanism of their action has not yet 
been fully elucidated, but they are inhibitors of osteoclast activity and inductors 
of their apoptosis, reducing the process of bone remodeling. Bisphosphonates are 
incorporated into the hydroxyapatite bone matrix, at the site of the OH group of 
bisphosphonates, using the P-C-P compound, which alters bone microstructure 
by slowing bone growth and reducing the amount of mineral dissolution in bone. 
Unlike osteoclasts, osteoblastic activity does not decrease, but remains preserved, 
which results in an increase in bone mass. There are currently three generations of 
bisphosphonates on the market. The first generation of nitrogen-free bisphospho-
nates has the least potential for jaw osteonecrosis. The main side effect of bisphos-
phonate therapy is osteonecrosis of the jaw [2]. Other side effects that may occur 
in bisphosphonate therapy are: gastrointestinal disorders (nausea and vomiting), 
atypical femoral fractures, esophageal inflammation with consequent mucosal 
erosions, secondary hyperparathyroidism, atrial fibrillation, eye outbursts, muscle 
pain and others [14–17]. Bisphosphonates are excreted by the kidneys, after accu-
mulation at sites of active remodeling (both jaws). Their characteristic is also rapid 
deposition in the bones and their long retention in the same (the half-life of zole-
dronic acid is 11.2 years in the bones) [18]. There are two types of bisphosphonate 
administration, oral and intravenously.
Oral bisphosphonates are medications that are most commonly prescribed 
in the treatment of osteoporosis and osteopenia, also they are the medications of 
choice for bone diseases that occur less frequently, such as Paget’s disease, osteo-
genesis imperfecta, chronic recurrent multifocal osteomyelitis and for prevention 
heterotopic ossifications mostly of the spinal cord [19, 20]. They are also indicated 
in treatment of chronic kidney disease, kidney transplantation, in rheumatoid 
diseases related with systemic bone loss such as rheumatoid arthritis, spondylar-
thritis or SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome and 
in non-inflammatory rheumatoid diseases, as aseptic osteonecrosis, neuropathic 
osteoarthropenia, and fibrous dysplasia [21]. Unlike intravenous bisphosphonates, 
have a lower potential for osteonecrosis.
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Intravenous bisphosphonates are the most potent in causing osteonecrosis 
[22]. They are used in the treatment of various conditions associated with malig-
nant diseases such as hypercalcemia caused by cancer and for treatment of bone 
metastases (secondaryism) [23]. Secondaryism in bones are releasing cytokines 
and growth factors, which enhance the effectiveness of osteoclasts and conse-
quently bone resorption, which favors tumor growth. Intravenous bisphosphonates 
stimulate antitumor immune mechanisms, which inhibit growth, migration, and 
secondary formation, most commonly in breast and prostate cancer. This type of 
bisphosphonates is very common used in treatment of lytic lesion and for preven-
tion of massive bone resorption in multiple myeloma. Patients with this diagnosis 
are often treated with aggressive chemotherapy which one of many side-effects is 
osteonecrosis. Despite the mentioned facts, these medications have positive effect 
on patient’s quality of life [24].
3.1.2 Denosumab
Denosumab are humanized monoclonal antibodies directed to a RANK ligand 
(modeling regulator) that inhibit osteoclasts and reduce bone resorption [25]. It 
is used for treatment of osteoporosis in which there is an increased risk of bone 
fractures, in osteoporosis where there is bone loss due to the use of various drugs 
and in the treatment of malignant bone lesions diseases. Denosumab therapy is 
a better option than bisphosphonate therapy, especially with renal dysfunction. 
The potency of denosumabs to induce osteonecrosis alone has been shown to be 
approximately similar to the potency of zoledronic acid which is the most potent 
bisphosphonate [26, 27].
Denosumabs are administered subcutaneously and, unlike bisphosphonates, do 
not accumulate in bone, so that their effect on bone remodeling is reversible and 
lasts approximately six months [28].
3.2 Antiangiogenic drugs
Antiangiogenic medications prevent the formation of new blood vessels binding 
to various signaling molecules that inhibit angiogenesis.
3.2.1 Bevacizumab
Bevacizumab is humanized monoclonal antibody that binds selectively to a 
protein called vascular endothelial growth factor (VEGF) in the blood and lymph 
vessels. It is used in the treatment of malignant diseases of the kidneys, gastrointes-
tinal tract, lungs and glioblastoma [9, 10].
3.2.2 Sunitinib
Sunitinib is used in the treatment of gastrointestinal tumors, metastatic renal 
cell carcinomas cells and neuroendocrine tumors of the pancreas. It works by 
inhibiting thyroxine kinase function. In combination with chemotherapy or 
bisphosphonates, they have high risk of inducing osteonecrosis [29].
4. Mechanism of development MRONJ
The exact mechanisms of development MRONJ are not todays completely 
resolved. It is thought that its development is a result from combination of 
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medication interactions, microbiological contamination of the area and local tissue 
trauma [30]. In the literature there are few hypotheses of the development of this 
specific disease.
4.1 Inhibition of bone resorption and remodeling
Antiresorptive medications inhibit osteoclast function and differentiation, 
leading to their apoptosis, and this results in reduced bone remodeling [31]. In 
addition to acting on osteoclasts, antiresorptive medications also reduce the activity 
of osteoblasts, keratinocytes and fibroblasts [32, 33]. Of all the bones, the jaws are 
the most susceptible to remodeling, so osteonecrosis specifically occurs on them.
4.2 Inflammation or infection
In the pathogenesis of medication-related osteonecrosis, inflammation plays a 
significant role development. Advanced periodontal disease and tooth extraction are 
one of the main triggers for occurrence of necrosis. Pathohistological analysis of bone 
parts, which are affected with osteonecrosis, decontamination with various bacteria 
is present, especially Actinomyces species in 70–100% of cases [34]. The main role in 
development of MRONJ has bacterial decontamination [35, 36]. Bisphosphonates 
have synergistic effect with bacteria because they increase the possibility of bacterial 
adhesion to hydroxyapatite found in the bone, resulting in the invasion of microor-
ganisms into the bone itself afterwards the bone loses blood supply, becomes avascu-
lar and necrotic.
4.3 Inhibition of angiogenesis
Inhibition of angiogenesis means inhibition of growth, migration and differen-
tiation of new endothelial cells in forming blood vessels. Medications that inhibit 
angiogenesis, due to ischemia or lack of blood supply to the bone secondary create 
osteonecrosis [37].
4.4 Soft tissue toxicity
One of theory of medication-related osteonecrosis is that drugs directly negatively 
affect fibroblasts producing toxicity of the oral mucosa. In vitro studies, increased 
apoptosis has been reported, especially in oral epithelial cells, after application 
bisphosphonates. Bone exposure and impaired healing caused by tissue toxicity play 
an important role in the development of osteonecrosis [38].
4.5 Immune dysfunction
Antiresorptive drugs together with other immunosuppressants such as cortico-
steroids, chemotherapy or methotrexate increases the possibility of osteonecrosis 
[3]. Ruggiero et al. [3] stated that in the beginning of investigating the influence of 
bisphosphonates on wound healing in animal models, to induce osteonecrosis, ste-
roids were combined with bisphosphonates. Inflammation, delayed healing, muco-
sal ulceration, exposed bone, fistula and histologic necrosis are well documented 
symptoms in different animal species and in humans exposed to surgical procedures 
after application chemotherapy with antiresorptive drugs. Methotrexat is standard 
or first line drug for therapy of rheumatoid arthritis. It can be an iatrogenic cause of 
lymphoproliferative disorders in immunodeficient or immunosuppressed patients, 
resulting with osteonecrosis of the jaw in some cases [35].
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4.6 Low pH values
Depending on the pH value, bisphosphonates can bind to hydroxyapatite in 
the bone or leave it and activate. At neutral pH the bisphosphonates are bound 
to hydroxyapatite and at reduced pH values bisphosphonates are released and 
activated from it [37, 38]. Bone resorption mechanism takes place in the Howship’s 
lacunae. In situations when the pH remains low, potentially leads to toxic levels of 
bisphosphonates which have a negative effect on osteoclasts and other cells as well. 
By acting on different types of cells, there is suppression of remodeling, suppres-
sion of angiogenesis, increasing the toxicity of the oral mucosa, which contributes 
creating an infection with developing the osteonecrosis [38].
5. Epidemiology of development MRONJ
The incidence of drug osteonecrosis depends on a variety of factors.
5.1 Method of application
The way of medication administration is an important factor in assessing the 
risk of developing osteonecrosis. Bisphosphonates taken orally have been shown 
to be more benign than bisphosphonates administered intravenously [3, 39]. The 
prevalence of medication related osteonecrosis in oral bisphosphonates is much 
lower (ranging from 0.1% to 0.05%) than the prevalence of intravenous bisphos-
phonates and denosumab (ranging from 2% to 10). Prevalence increases after inva-
sive surgical procedure and also increases with the duration of therapy. The largest 
prevalence of medication-related osteonecrosis has been described in patients with 
multiple myeloma [22, 40].
5.2 Duration of therapy
An important factor in the development of medication related osteonecrosis is 
the duration of the antiresorptive therapy. The literature states that after each year 
of therapy, the risk of medication osteonecrosis doubles [41].
5.3 Dosage
Medications that cause MRONJ can be prescribed every day, once weekly, once 
a month, once every three months or once every six months. Incidence of osteone-
crosis increases with a higher dose [42–45].
5.4 Potency
Almost every antiresorptive medication shows its potency in causing osteone-
crosis [42].
5.5 Accumulation in the body
Zoledronic acid and denosumab have similar potency of inducing osteonecrosis. 
They are different in the time of accumulation in the body. Bisphosphonates accumu-
late in bones, where they persist for a long time, their half-life last up to 11.2 years, 
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while unlike bisphosphonates, denosumabs do not accumulate in the bones and are 
eliminated from the body after only 6 months [28, 46].
5.6 Local factors
Dental procedures that are invasive, such as dentoalveolar surgery, increase the 
risk of MRONJ up to seven times [3]. From local factors dentoalveolar surgery is 
considered the most risky factor for the development of medication-related osteo-
necrosis with an incidence of 60 to 65% [31, 47]. In other dental procedures such as 
endodontic or periodontal, the incidence of medication-related osteonecrosis is less. 
Dental diseases that the patient has already overcome, such as periodontitis, peri-
implantitis, various inflammatory conditions of the jaw and poor oral hygiene are 
among the additional risk factors conducive to the development of MRONJ [47, 48].
5.7 Anatomical factors
It is known that medication related osteonecrosis occurs more often in the lower 
jaw in 73% of cases relative to the upper jaw, where it occurs in 22.5% of cases, while 
the incidence of osteonecrosis in both jaws simultaneously only in 4.5% of cases [3]. 
It also turned out that MRONJ more often develops in places with the thinnest layer 
of mucosa, and these are the lingual side of the lower jaw and the various exostoses 
and toruses found in the oral cavity [3, 47]. Wearing a prosthesis is also doubling 
the risk of developing MRONJ.
5.8 Systemic factors
A significant risk factor for the development of MRONJ is the patient’s basic 
disease [49]. An increased risk of medication-related osteonecrosis has been 
shown in women, mostly due to osteoporosis or breast cancer. A risk of MRONJ 
significantly increases if, in addition to antiresorptive therapy are added additional 
drugs that act immunosuppressively, such as chemotherapeutics or corticosteroids. 
Studies show that MRONJ occurs in 40% of cases in patients who have been or are 
still on chemotherapy, in 25% cases of patients on corticosteroid therapy and in 
10% of patients with diabetes [50, 51]. Anemia, systemic lupus, hypothyroidism, 
renal failure, rheumatoid arthritis, hypertension and smoking are also conditions 
that contribute to an increased risk of osteonecrosis [52, 53].
5.9 Genetics
The risk of developing osteonecrosis is also associated with gene predisposition. 
Some studies have shown an association between the FDPS (farnesyl diphosphate syn-
thase gene) which encodes a key enzyme of the mevalonate pathway and the develop-
ment of osteonecrosis of the jaw. That is why are tested rs2297480, a SNP region on the 
FDPS gene. Studies have been conducted in patients who have suffered from multiple 
myeloma or metastatic carcinomas and have been treated with zoledronate acid [54].
5.10 Biomarkers for risk assessment
Bone markers have been shown to be useful for assessing the risk of developing 
osteonecrosis [47]. C-terminal telopeptide (CTX) and N-terminal telopeptide (NTX) 
are demonstrated as the two main bone markers that measure osteoclast activity, i.e., 
degradation of osteoclasts and osteoblasts [47].
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6. Prevention of MRONJ
6.1 Before starting antiresorptive therapy
Before starting antiresorptive therapy, it is important to make an initial dental 
examination with a detailed history and radiologically and clinically evaluate the 
patient’s condition. An orthopantomogram is recommended of the radiological 
techniques. The goal of preventive screening is to remove any potential conditions 
that could lead to the formation of osteonecrosis during therapy. It is necessary 
to remove all incurable teeth or teeth with a poor prognosis, cure acute or chronic 
infections, cysts, tumors and other pathological conditions of the jaw. If the patient 
has a prosthesis, it is necessary to examine the sharp edges or possible painful areas 
(“blistering”) that may adversely affect the mucosa. If teeth need to be extracted, 
it is advisable to wait a minimum of three weeks to achieve acceptable soft tissue 
healing, or preferably four to six weeks to achieve sufficient bone healing before 
initiating antiresorptive therapy [3].
Patients need to be educated about the risk of developing osteonecrosis, moti-
vate them to strengthen oral hygiene and more frequent control (at least four times 
a year).
6.2 After therapy/during therapy
Depending on the duration and manner of taking antiresorptive drugs, it is 
necessary to make a detailed treatment plan that includes a consultation with a 
competent doctor for possible withdrawal of therapy.
Invasive surgical procedures (extraction, endodontic surgery) are reported as an 
increased risk of creating necrosis itself. In high-risk patients (high-potency drugs, 
adjunctive therapy), for the development of osteonecrosis, tooth extraction is not 
recommended and instead of extraction, endodontic treatment is recommended 
with root smoothing and cement coating. However, if invasive surgery is required as 
indicated for severe periodontitis, movable teeth, root fractures, then it is advisable 
to use the recommended guidelines [3].
A. Oral bisphosphonates.
1. If the patient is on therapy for less than four years and is not on adjunctive 
therapy (corticosteroids or angiogenic drugs), antiresorptive therapy does 
not need to be removed.
2. If the patient is on therapy for less than four years and prescribes adjunctive 
therapy (corticosteroids or angiogenic drugs) or is on therapy for more than 
four years or without adjunctive therapy, then consultation with a physician 
is required to discontinue bisphosphonate therapy at least two months before 
surgical treatment and continuation of bisphosphonate therapy when adequate 
bone healing is achieved (usually three months after the surgical treatment) [3].
B. Denosumabs.
Denosumabs are most commonly taken subcutaneously every six months. If 
invasive surgery is required, it is recommended to do it three weeks before the next 
application of the drug itself. It should be in mind that denosumabs are extremely 
potent drugs for the formation of osteonecrosis, but they, unlike bisphosphonates, 
are eliminated from the tissues after six months [3].
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C. Parenteral bisphosphonates.
The previous recommendation was to discontinue therapy six months before 
the procedure and three months after, but this is especially difficult in malignant 
patients (due to the severity of the underlying disease) and discontinuation of 
therapy has not been scientifically proven to reduce the risk of osteonecrosis. It is 
recommended that the patient be referred to a specialist institution for the most 
at-risk group. Poor soft tissue healing should be in mind in patients receiving 
chemotherapy, especially three to four weeks after chemotherapy when mucositis of 
the oral mucosa is most common [3].
7. Clinical aspect of MRONJ
To diagnose medication related osteonecrosis of the jaws the following criteria 
must be filled:
1. Current or previous therapy with antiresorptive or antiangiogenic 
 medications;
2. Exposed bone or appearance of a fistula in the jaw (intraoral or extraoral) 
that persists longer from eight weeks;
3. The patient is not irradiated and has no proven metastasis in the jaw bones [3, 55].
Medication-related osteonecrosis significantly impairs the quality of life of the 
patient and represents problems with speech, chewing, swallowing, feeding, often 
there is pain in the swollen mucosa, as well as chronic sinusitis [3]. In almost 94% of 
cases of medication-related osteonecrosis, exposed bone is present [56]. It is also the 
main feature of osteonecrosis (Figure 1). Variations can be different, from the small 
exposed edges around the empty alveoli all the way to complete involvement of one 
or both jaws [57]. We often find next to the exposed bone and signs of inflamma-
tion of the surrounding soft tissues that present as swelling that may or may not be 
purulent. The most lesions are asymptomatic, and when the patient develops pain, 
Figure 1. 
Clinical appearance of MRONJ-exposed bone (Zometa).
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we often find signs of acute inflammation in the surrounding tissue. In two-thirds 
of cases, medication-related osteonecrosis is found in the lower jaw [58]. The reason 
for this is a thinner mucosa than in the upper jaw and poorer blood supply to the 
lower jaw. Patients suffering from malignant diseases are most predisposed to 
MRONJ so it is very important to estimate whether the symptoms of progression are 
consequences osteonecrosis itself or are symptoms of secondaryism. After removal 
of the necrotic part of the bone, it is recommended to send materials for pathohisto-
logical analysis to determine the persistence of necrosis or some other lesions.
7.1 The course of the disease
The course of the disease itself can vary. Lesions can be limited and at 
dormancy stage or can spread to surrounding structures. MRONJ can spread 
all the way to the mandibular canal or maxillary sinus. In such cases, there are 
symptoms such as numbness, sinus infection and even the formation of oroantral 
communication. By spreading necrotic lesions it can also lead to pathological 
fractures of the jaw, which are serious, therapeutic and functional problems. 
Pathological fractures (Figure 2) are not common, they occur in 3% of patients 
who are treated from MRONJ [3].
8. Radiological characteristics of MRONJ
The involvement of the region by medication-related osteonecrosis can be 
assessed by radiographic analysis. This type of imaging is also useful in monitoring 
the disease and in diagnosing complications that occur in osteonecrosis such as 
fractures and sinusitis. By radiological analysis we can detect different stages of the 
disease and even the zero stage. Two-dimensional panoramic images (Figure 3) are 
recommended as an initial radiographic technique that give an excellent overview 
of the bones, teeth and the surrounding structure. Sclerosis found in the lamina 
dura of the alveolar ridge, after radiological examination, is the most common 
radiological change at risk patients. We can also find others radiological changes that 
are not so common, namely: sclerosis of the marginal parts of the jaw (most com-
monly in the mandible), narrowing of the mandibular canal, difficult or complete 
absence of healing of postextraction alveoli, radiolucent regions around the bone 
corresponding to osteolysis and necrotic bone sequesters that occur in the later 
stages of medication-related osteonecrosis [59–61]. More precisely, the lesion can be 
represented by one of the three-dimensional display techniques such as computed 
Figure 2. 
Spontaneous bilateral mandibular fracture (Aredia).
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tomography or cone-beam computed tomography. In the CBCT scan (Figure 4) 
we can get more precise data on the localization and on the progression of the 
disease and useful data on the surrounding bone structures. At early diagnosis of 
MRONJ, magnetic resonance (MRI), single-photon emission computed tomography 
(SPECT) and positron emission tomography with computed tomography (PET/CT) 
were also proved as an excellent diagnostic tool [59, 62–67].
9. Classification of MRONJ
The disease, according to the clinical picture and the appearance of symptoms of 
osteonecrosis, is classified into four stages [3].
Figure 3. 
MRONJ in a patient with multiple myeloma and treated with zoledronic acid (Zometa).
Figure 4. 
CBCT scan (of same patient as in Figure 1) after surgical treatment.
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9.1 Stage 0
This stage of disease includes patients who have not clinically developed osteo-
necrosis but have nonspecific symptoms or radiological signs that may be associated 
with therapy. Symptoms associated with stage zero are: unexplained odontalgia, 
dull pain of lower jaw extending toward the temporomandibular joint, sinus pain 
that may be associated with inflammation and narrowing of the bone wall toward 
the sinus [3]. Clinical findings that may indicate stage zero are: unexplained tooth 
loss unrelated to chronic periodontal disease, periapical/periodontal fistula unre-
lated to pulp necrosis or caries, unexplained gingival swelling. Radiological signs 
are: loss of alveolar bone or resorption not related to chronic periodontitis, changes 
in the composition of the trabeculae, difficult (delayed) wound healing after tooth 
extraction, sclerosing regions of the alveolar part (thickening of the lamina dura, or 
reduction of the space belonging to the periodontal ligament) or surrounding part 
of the bone [66–68].
Zero-stage therapy is symptomatic and conservative, aimed at remediation 
of predisposing conditions that can cause osteonecrosis (remediation of caries, 
periodontal diseases, other pathological conditions, inadequate dentures). It is also 
necessary to exclude other diseases such as fibroseal lesions, chronic sclerosing 
osteomyelitis and others.
Patients need to be educated about the disease, about adequate oral hygiene and 
encouraged to have more frequent check-ups (at least every two months).
9.2 Stage 1
Stage one of the disease describes clinically exposed necrotic bone or the appear-
ance of a fistula that forms from the bone, however patients have no symptoms and 
no signs of acute infection. The time required for proper diagnosis of the first stage 
of disease is eight weeks from appearance of exposed bone or fistula [3].
First-stage therapy is primarily aimed at monitoring the lesion. If necrotic bone 
sequesters or sharp bone margins occur, they should be removed. Monitoring the 
condition of the surrounding mucosa is extremely important for further prognosis 
of the disease.
It is also necessary to educate and motivate patients for frequent checkups.
9.3 Stage 2
Stage two describes clinically exposed necrotic bone or the appearance of a 
fistula that forms from bone with signs of acute infection accompanied by pain [3].
Stage two therapy is initially aimed at repairing the inflammation and antibiotic 
therapy is often attributed to it in combination with antimicrobial washes (most 
commonly chlorhexidine). Necrotic bone is often contaminated with bacteria 
to form biofilms that may be resistant to antibiotic therapy. After repairing the 
inflammation, it is necessary to remove the necrotic part of the bone and the 
inflamed mucosa.
9.4 Stage 3
Stage three describes clinically exposed necrotic bone or the appearance of a 
fistula that forms from bone with signs of acute infection accompanied by pain and 
at least one of these signs: spreading necrosis outside the dental alveolus (lower 
edge and ascending part of mandible, maxillary sinus, toward the cheekbone), the 
appearance of extraoral fistula, osteolysis of the lower border of the lower jaw and 
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the bottom of the maxillary sinus with the appearance of oroantral communication 
and the appearance of pathological fractures [3].
Third-stage therapy focuses on palliative therapy that includes debridement or 
resection of the lesion in combination with antibiotic therapy to eliminate acute 
infection and pain. Therapy directly depends on the health condition of the patient. 
If larger resections are performed, reconstruction is performed by different recon-
structive methods (fibula graft) with or without obturator.
10. MRONJ treatment protocol
There is currently no gold standard or clearly defined treatment protocol for the 
disease itself.
If osteonecrosis of the jaw occurs, it is recommended that the patient be referred 
to an oral or maxillofacial surgery specialist for further treatment.
The goals of therapy are aimed at eliminating inflammation and pain by pre-
venting or slowing the progression of the disease. Before treatment, it is necessary 
to take a detailed medical and dental history and consult a doctor about the possible 
removal of the drug. Treatment depends on the degree of the disease and is initially 
focused on antibiotic therapy in combination with antimicrobial therapy and 
analgesics. Surgical techniques for removing the necrotic part of the bone include 
sequestration, ridge modeling, resection of the jaw with various reconstructive 
methods [3].
American Association of Oral and Maxillofacial Surgeons (AAOMS) recom-
mends starting conservative therapy before surgery [3]. Conservative therapy 
serves to control the disease itself and is achieved by antibiotic therapy and 
chlorhexidine rinsing. They believe that elective surgery can lead to further 
disease progression. If the disease progresses then surgery needs to remove the 
necrotic lesion. On the other hand, European guidelines recommend the initial 
surgical removal of the necrotic part of the bone regardless of the degree of the 
disease for several reasons: the necrotic part of the bone cannot be revitalized and 
it is the entrance door for colonization of bacteria and fungi [69–71]. Histological 
processing is recommended to demonstrate necrosis and differential diagnosis 
in the form of bone metastases, osteomyelitis (inflammatory bone condition) or 
osteoradionecrosis (radiation-related ischemic bone necrosis) [72].
Surgical procedures have been scientifically proven to perform better compared 
to a conservative approach [73–76]. Conservative treatment consists of more fre-
quent follow-up examinations (once or twice a week) for months, which is a burden 
for patients. It should be in mind that frequent check-ups are difficult for oncology 
patients.
The success of the therapy is achieved when the necrotic part of the bone is 
removed and when the mucosal integrity of the tissue is established. Treatment of 
MRONJ should be divided into bone and soft tissue repair. After removal of the 
necrotic part of the bone or tooth extraction, it is necessary to keep in mind the 
smoothing or modeling of sharp sclerotic bone edges of the wound because they 
remodel very slowly and can potentiate the development of necrosis (Figure 5). 
After removal of the necrotic part, it is necessary to process the soft tissue. The 
aim is to achieve optimal marginal closure of the wound in the form of preventing 
the penetration of microorganisms, i.e., contamination of the surrounding bone. 
Mucosal integrity is achieved by primary suturing of the wound without tension. 
Some surgeons recommend double covering the exposed portion of the bone with 
a muscle flap (m. mylohyoideus) or buccal fat pad flap [77–79]. For larger defects, 
reconstruction with a microvascular skin or bone graft is recommended, however, it 
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should be considered that the transplanted bone is also rich in antiresorptive drugs. 
Major reconstructions depend on the health status of the patients.
The necrotic portion of the bone relative to the surrounding healthy bone tissue 
may be clearly limited (sequestration formation) or may be diffusely incorporated 
into healthy bone tissue. Clearly demarcated sequesters are easily removed during 
surgery, while diffuse parts are difficult to remove due to the unclear boundary of 
necrotic from vital bone tissue [80, 81]. Bone bleeding was previously thought to 
be a sign of vitality (which makes it easier for surgeons to work) however, this has 
proven to be wrong. For the treatment of diffuse lesions, the use of fluorescence in 
combination with tetracycline is recommended [82, 83].
11. Photodynamic therapy and MRONJ
There are various additional methods of treatment, in addition to surgical treat-
ment, that promote healing of the lesion. For this purpose oxygen therapy (ozone, 
hyperbaric chamber), hormone therapy (parathyroid hormone), growth factor 
(Figure 6) therapy (PRP, PRF, PRGF, BMP), mesenchymal stem cell therapy and a 
combination of pantophilin and tocopherol [84–88] are used.
Vescovi et al. [89] in 2006 described the application of low-level-laser therapy 
(LLLT) as possible treatment of osteonecrosis of the jaw. The effect of lasers is 
classified in two categories, regarding its mW range: biostimulation (LLLT) and 
photodynamic therapy (PDT). Main difference between this two types is that in 
biostimulation therapy (LLLT) the laser acts directly on the tissue and aims to 
Figure 6. 
Augmentation using autologous growth factors; PRGF technique, F2 and F1 phase.
Figure 5. 
Surgical treatment- modeling of sharp sclerotic bone edges.
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support tissue healing, while in photodynamic therapy (PDT) it acts on chemical 
medium (photosensitizer) (Figure 7) which induces cell (e.g. bacteria) and tissue 
damage as a chemical effect [90].
LLLT has from clinical point of view become adjuvant medical tool for 
enhancing wound-healing process, so some clinical studies reported laser-
induced stimulation especially of soft tissue healing such as ulcers and postopera-
tive wound dehiscences [91, 92]. Stein et al. [93]. in their in vitro study confirmed 
that low energy laser irradiation promotes proliferation and maturation of human 
osteoblasts, while stimulating effect of LLLT is explained by an increase of ATP in 
affected cells [94].
Photodynamic therapy (PDT) is being increasingly used in the management of 
MRONJ in combination with other therapeutic choices [90].
In the beginning photodynamic therapy (PDT) was used particularly to treat 
cancer and several studies have shown its antimicrobial potency [95–98]. Analyzing 
the effects of PDT on osteoblasts growth, study by Zancanela et al. [99] showed 
that PDT results in biostimulation of osteoblastic cell cultures or a cytotoxic 
effect depends of the applied dose. PDT has well documented clinical impact as 
adjuvant local treatment of ulcers and infected wounds, and potential indications 
for therapy of periodontitis and peri-implantitis, but treatment of MRONJ still 
in phase of collecting clinical results [100–105]. Treatment concept of MRONJ 
with PDT describes its use for symptomatic treatment in stage 0, preoperatively to 
reduce bacterial load and in cases with healing deficiencies, while in stages 1, 2 and 
3 it is used after surgical treatment. Also it may be used as adjuvant conservative 
intervention for palliative therapy of compromised patients or in cases to avoid 
progression of disease when patients refuse surgery.
While application of LLLT for therapy of MRONJ has been described in numer-
ous studies, there are few studies mainly focused on impact of photodynamic 
therapy of preventing occurrence of MRONJ. Vescovi et al. [89] used Nd:YAG laser 
biostimulation in addition to medical and surgical therapy and demonstrate a 
better healing tendency due to bony ablation, bactericidal and detoxification effect 
[106, 107]. Da Guarda et al. [108] reported a case of successful MRONJ treatment 
with the GaAIAs diode laser in combination with bone curettage. Summarizing the 
literature, use of LLLT is beneficial for treatment of MRONJ, although till today 
there are no large studies that proves significant improvement.
One of promoting factor in mechanism of MRONJ is presence of microflora. 
Species such as Fusobacterium, Eikenella, Bacillus, Actinomyces, Staphylococcus, and 
Streptococcus are predisposed to survive in oxygen depleted areas of necrotic bone 
that lack blood supply [109, 110]. Although the identification of microbial biofilms 
Figure 7. 
Application of chemical medium (photosensitizer)- toluidine blue.
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and Actinomyces species as the leading bacterial pathogen isolated from patients 
with MRONJ, there is unclear definitive treatment and no data reffering to bacteri-
cidal activity of laser therapy against Actinomyces species in MRONJ lesions.
The most used PDT system is one with mobile diode laser and dye (HELBO) 
with methylene blue (MB) (Figure 8). It has shown very promising results during 
surgical procedures or as adjuvant therapy in cases of postoperative wound dehis-
cences in patients with MRONJ. Photosensitizers’s antimicrobial activity is mediated 
by singlet oxygen, which has high chemical reactivity and results with a direct effect 
on extracellular molecules. The polysaccharides present in extracellular matrix of a 
bacterial biofilm are sensitive to photodamage, so breaking biofilms can interrupt 
colonization and prevent antibiotic resistance [111].
Although is surgical treatment first option to deal with MRONJ, appliance of 
photodynamic therapy has several advantages. Before surgery usually we treat 
symptoms of MRONJ infection, such as swelling, purulent discharge and pain. They 
can be managed by bio-stimulative effect of the laser, especially those with advanced 
primary disease or those suffering from other sickness resulting in a general poor 
health [90]. PDT might be very sufficient in early stages of osteonecrosis promoting 
secondary granulation and formation of mucosal coverage, so surgery can be avoid. 
Unfortunately there are no controlled studies opposing PDT and LLLT to evalu-
ate use of photosensitizer. Appliance of photodynamic therapy immediately after 
surgery could decrease complications of impaired healing of the wound (Figure 9).
In conclusion, although MRONJ is considered difficult to treat and may even 
be recalcitrant to therapy, photodynamic therapy can be a viable supportive tool 
Figure 8. 
Antimicrobial photodynamic therapy using low-power diode laser (aPDT mode, LaserHF, 
HagernnnnnWerken).
Figure 9. 
MRONJ before and 2 months after treatment with combined therapy (surgery/aPDT/PRGF).
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